Objective: To evaluate provider acceptance of pharmacist interventions within the Discharge Companion Program (DCP) and its association with hospital readmissions. Methods: This retrospective record review included patients referred to the DCP between January and October 2018. DCP pharmacists' interventions were assessed for provider acceptance on follow-up consultation or readmission. A chi-square test assessed the association between provider acceptance, communication modality, and technology used. A logistic regression model assessed the association between readmission risk and variables of interest. An a priori alpha level of 0.05 was used. Results: Of the 197 patients referred to the DCP, 102 met inclusion criteria. DCP pharmacists made a total of 271 interventions; 185 (68.7%) required provider action. The most common intervention type was medication addition or discontinuation (n ¼ 74, 40%); the communication mode was between DCP nurses and primary care provider offices or skilled nursing facilities (n ¼ 56, 54.9%); and the preferred technology was the telephone (n ¼ 58, 56.9%). Provider acceptance rate was 30.8% (n ¼ 57) of actionable interventions, although it was not significantly associated with 30-day readmission reductions (P ¼ 0.833) and did not differ significantly when interventions were communicated to other health care professionals (P ¼ 0.53). The specific intervention communication mode (i.e., telephone, facsimile, or both) of pharmacist interventions did not significantly affect provider acceptance (P ¼ 0.133). The overall readmission rate was 22.5% (n ¼ 23), and the only significant predictor of 30-day readmission was the number of comorbidities (odds ratio 1.28 [95% CI 1.03e1.58], P ¼ 0.024). Conclusion: Provider acceptance of pharmacists' interventions did not significantly affect 30-day readmission rates, regardless of communication mode (telephone or facsimile) or technology used. However, the DCP successfully identified numerous medication-related problems. Further study is warranted regarding provider acceptance of pharmacist recommendations on 30-day readmission reduction.
a 2.4-fold increase in the odds of readmission. 3 Furthermore, polypharmacy may increase the risk of 30-day readmission by 9.6%. 4 Thus, a gap exists regarding strategies to reduce MRP-associated hospital readmissions.
Pharmacists are uniquely positioned to help patients manage their medications for their chronic conditions. Furthermore, a telephonic consultation with a pharmacist after discharge can reduce 30-day readmissions by identifying MRPs. 5 Studies have found that pharmacist interventions can lead to a statistically significant reduction in readmissions ranging from 3.3% to 30.0% as a result of pharmacist-delivered medication reconciliation, patient education, medication management, or care coordination. 5 It is widely accepted that telepharmacy allows for expanded coverage of pharmacy services, improved patient safety, and improved communication between patients, health care providers, and pharmacists. 6 Furthermore, the American Society of Health-System Pharmacists supports telepharmacy as well as advocates for more research to investigate telepharmacy-related best practices. 6 Although hospital pharmacist medication reviews have an impact on patient outcomes, physician acceptance of pharmacist interventions ranges from 39% to 90%. 7 However, studies specifically evaluating provider acceptance of telepharmacy interventions are scarce. Only 1 study reported that provider acceptance of telepharmacist intervention occurred in one-third of those performed (n ¼ 75, 37.5%). 8 To date, no study has assessed the sensitivity of provider acceptance regarding factors such as mode of communication nor the relationship between provider acceptance of pharmacist interventions and 30-day readmission. The Discharge Companion Program (DCP), an interprofessional care transitions partnership with a local hospital and a medication therapy management service provider in southern Arizona, was developed to address this gap in the existing literature.
Objectives
The aims of this study were to evaluate: the rate of provider acceptance of pharmacist intervention and its association with readmission rates; and the effectiveness of different communication modalities on provider acceptance of pharmacist interventions.
Methods

Program description
The DCP is an interprofessional partnership between a local hospital in southern Arizona and a national medication therapy management (MTM) service provider. The program was established to integrate with the hospital's existing transitional care team. It aimed at reducing readmissions, improving patient health outcomes, and decreasing patientand hospital-related costs. Patients discharged from the hospital with a high risk of readmission diagnoses, defined by the Hospital Readmission Reduction Program (HRRP) of the Centers for Medicare and Medicaid Services (CMS), 9 as well as additional diagnoses were referred to the DCP and underwent an interprofessional evaluation, including a pharmacy assessment. Program pharmacists performed a review of patients' discharge medications and conducted 2 telephonic consultations with patients: within the first week of discharge and 3 weeks after discharge. Interventions were communicated to patients' providers using a variety of communication modalities and telehealth technologies. Preliminary data from the DCP suggest that pharmacist involvement in the discharge process reduced the risk of 30-day readmission by 14.8% compared to readmission rates of usual care patients. 10 
Study design
This retrospective review included data collected between January and October 2018. Participants were included in the study if they received an initial pharmacist consultation within 1 week of discharge. Patients were excluded if they: had a hospital readmission before completion of the initial consultation; had no pharmacist interventions documented after completion of the initial consultation: or were considered lost to follow-up between the initial and follow-up consultation. This retrospective review was approved by the institutional review board (No. 1812207798).
Data collection
Data were collected for patient demographics, discharge diagnosis and disposition, number and type of pharmacist interventions, and number of comorbidities. For each eligible patient, pharmacist documentation was reviewed to collect information on: interventions performed, including the number of accepted interventions on follow-up consultation or readmission; technology used to transmit interventions:communication modality used: and readmission within 30 days. Readmission cases were defined as patients readmitted to the local hospital within 30 days of discharge per CMS's HRRP. 9 The technologies used to transmit pharmacist interventions included telephone and facsimile, and the communication modalities included those between DCP nurses and medical assistants (MAs), DCP nurses and primary care provider (PCP) offices or skilled nursing facility (SNF) staff, or DCP nurses and other pharmacists involved in the care of patients outside of the DCP (e.g., pharmacists at SNFs). All patient data were de-identified and password-protected, and access was limited to study investigators alone.
Study outcomes
The primary outcome was the association of provider acceptance of pharmacist interventions with 30-day readmission rates. The secondary outcomes included establishing an overall rate of provider acceptance of DCP pharmacist interventions and investigating the association between provider acceptance rates and the communication modality or technology used. Statistical analysis was performed using chi-square tests to assess the association between provider acceptance, 30-day readmission, communication modality, and technology used. A multivariate logistic regression model assessed the association between readmission risk and other variables of interest. The variables of interest used in the multivariate logistic regression were discharge diagnosis, comorbidities, communication modalities, and discharge disposition. All tests used an a priori alpha level of 0.05. Data analysis was conducted using IBM SPSS Statistics v2015 (IBM Corp, Armonk, NY).
Results
A total of 197 patients were referred to the DCP. Of these, 102 met the inclusion criteria and were included in the retrospective analysis. Figure 1 details the number of patients referred to the DCP and the final sample included in the retrospective review after the exclusion criteria were applied.
Most patients were women (51%), had a median age of 78 years (range 37 to 89 years), and had an average of 6 comorbidities. The most common discharge diagnoses were acute coronary syndrome (20.6%), congestive heart failure (18.6%), and pneumonia (14.7%). Most patients who received a DCP referral were discharged home (41.2%), with 21.6% receiving home-health services and 37.3% discharged to an SNF. Table 1 highlights the demographic characteristics of patients included in this retrospective analysis.
DCP pharmacists made a total of 271 interventions. Of these, 185 (68.7%) required provider action (actionable) or acceptance of the telepharmacist intervention. The most common: actionable intervention type was medication addition or discontinuation (n ¼ 74, 40%); intervention communication modality was between DCP nurses and PCP offices/ SNFs (n ¼ 56, 54.9%); and technology used to transmit pharmacists' interventions was telephone (n ¼ 58, 56.9%). The provider acceptance rate was 30.8% (n ¼ 57) of actionable interventions.
Overall, 23 patients (22.5%) referred to the program between January and October 2018 were readmitted within 30 days of discharge. Interestingly, provider acceptance was neither associated with a statistically significant reduction in 30-day readmission rates (P ¼ 0.833) nor significantly different when interventions were communicated to other pharmacists, MAs, or PCP office or SNF staff (P ¼ 0.53). Provider acceptance did not differ when the technology used to communicate interventions was telephone, facsimile, or both (P ¼ 0.133). The only significant predictor of 30-day readmission was the number of comorbidities (odds ratio 1.28 [95% CI 1.03e1.58], P ¼ 0.024), whereas discharge diagnosis, communication modalities, and discharge disposition were not.
Discussion
Pharmacists, on average, identified more than 2 MRPs per patient, thus highlighting the critical role they played in the DCP. They regularly identified actual or potential MRPs from telephone consultations and intervened to minimize their impact. However, the rate of provider acceptance of pharmacist interventions was not associated with reduced 30-day readmissions.
The study results suggest that the current technology deployed in the DCP may be improved upon to increase provider acceptance of the pharmacists' interventions. Nonetheless, the 30.8% provider acceptance rate of actionable interventions is lower than, albeit comparable with, the 37.5% rate reported in literature. 8 One possible explanation for the lower rate in the current study is that the provider interventions were communicated using a telephone or facsimile. In contrast, other studies with higher acceptance rates have integrated the documentation of the pharmacist interventions directly in the electronic health record (EHR), potentially a more convenient and readily available technology for communicating with the patient's provider. 8 In the current study, it was not possible to control for providers within the same hospital health system to assess whether access to the EHR had any effect on acceptance rates.
The association between pharmacists' DCP interventions and 30-day readmissions was not evaluated previously. Interestingly, the current study failed to show a link between provider acceptance of pharmacists' recommended intervention and 30-day readmission rates. Although a few studies report on provider acceptance of pharmacist Discharge Companion Program and its readmission reduction SCIENCE AND PRACTICE recommendations in nonhospital practice settings, none discuss the association with 30-day readmissions. In general, provider acceptance of pharmacist recommendations is relatively high. A recent systematic review assessing the impact of hospital pharmacist medication reviews on patient outcomes reported intervention acceptance rates ranging from 69% to 90%. 7 However, these studies were hospital-based, suggesting that most interventions were likely made during face-to-face interactions between the hospital pharmacists and physicians, which may help explain the higher acceptance rates. However, future work is warranted to investigate the association between provider acceptance rates of pharmacist interventions and 30-day readmissions.
Although the DCP interventions were communicated via telephone, facsimile, or both, acceptance rates were not significantly associated with the type of technology used or with the communication modality (DCP nurse to pharmacists, MAs, PCP office, or SNF staff). Thus, in this study, this may suggest that the technology used or mode of communication played a less critical role in provider acceptance of pharmacist interventions. The pharmacists' interventions were communicated to the provider's agent (medical doctor office [MDO]) or to the provider directly. However, it was very difficult or impossible to ensure that providers received the communication, especially given that it was not formally documented whether it was a specific staff person or the provider who received the pharmacist's recommendations. Thus, this also may help explain, in part, the lower acceptance rate observed in the current study.
The current study findings identified the number of comorbidities as the only variable significantly associated with 30-day readmission. This may suggest a need to emphasize better disease control and discharge planning of patients' comorbid conditions to help reduce 30-day readmission rates rather than focusing solely on the diagnosis at admission. This parallels other published studies that highlight the increased risk of 30-day readmission with increased scores in the Charlson Comorbidity Index, 4 a measure of an individual's burden of disease and corresponding 1-year mortality risk. 11 This study focused on the relationship between provider acceptance of pharmacist interventions and 30-day readmission rates. However, patient counseling is another important aspect of postdischarge, pharmacist-delivered consultations not captured in this study. Educating patients regarding their discharge medications may help reduce readmissions resulting from MRPs as well as may explain the DCP's success in reducing readmissions. 10 Counseling discharge patients regarding the medications prescribed and how, why, and when to take them, along with potential adverse effects, may result in absolute readmission reduction between 17.1% and 30.5%. 5 Therefore, future research warrants investigating the role of medication counseling in a transitional care program and its effect on 30-day readmission rates.
One strength of this current study is that it builds on the initial evidence surrounding the DCP. 10 No other studies consider the effect of provider acceptance of pharmacist interventions, within a transition of care program, on 30-day readmissions. In addition, it highlights the need for better collaboration between pharmacists and community-based providers to ensure treatment efficacy and patient safety beyond discharge.
Limitations
The study had several limitations. First, this was a retrospective study, and additional information to help validate specific information (e.g., whether the pharmacists' interventions were communicated to an agent of the provider or the provider) was not available. Second, the small sample size was a limitation because of the large number of excluded referrals. Excluding patients who were readmitted without a pharmacist consultation or who were unreachable was necessary to specifically assess the impact of pharmacist interventions. A considerable limitation of the current study was that there were no means for controlling for providers within the same hospital health system to assess whether having EHR access would have positively affected their acceptance rate (e.g., increased acceptance rates).
Conclusion
The DCP, an interprofessional, collaborative transitions of care program, was successful in identifying numerous MRPs, emphasizing the value of the pharmacists' role in the interprofessional health care team and the importance of effective communication among the collaborative team members. The number of comorbidities was linked to 30-day readmissions, whereas provider acceptance of pharmacists' recommended interventions was not. Thus, further research is warranted to study factors influencing provider acceptance of pharmacist recommendations in reducing 30-day readmissions through use of enhanced communication modalities and technologies (e.g., EHR) among interprofessional collaborative teams.
